204 related articles for article (PubMed ID: 23109060)
1. Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation.
Chien YH; Bodamer OA; Chiang SC; Mascher H; Hung C; Hwu WL
J Inherit Metab Dis; 2013 Sep; 36(5):881-5. PubMed ID: 23109060
[TBL] [Abstract][Full Text] [Related]
2. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A).
Liu HC; Lin HY; Yang CF; Liao HC; Hsu TR; Lo CW; Chang FP; Huang CK; Lu YH; Lin SP; Yu WC; Niu DM
Orphanet J Rare Dis; 2014 Jul; 9():111. PubMed ID: 25047006
[TBL] [Abstract][Full Text] [Related]
3. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
[TBL] [Abstract][Full Text] [Related]
4. Analysis of lyso-globotriaosylsphingosine in dried blood spots.
Johnson B; Mascher H; Mascher D; Legnini E; Hung CY; Dajnoki A; Chien YH; Maródi L; Hwu WL; Bodamer OA
Ann Lab Med; 2013 Jul; 33(4):274-8. PubMed ID: 23826564
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.
Maruyama H; Miyata K; Mikame M; Taguchi A; Guili C; Shimura M; Murayama K; Inoue T; Yamamoto S; Sugimura K; Tamita K; Kawasaki T; Kajihara J; Onishi A; Sugiyama H; Sakai T; Murata I; Oda T; Toyoda S; Hanawa K; Fujimura T; Ura S; Matsumura M; Takano H; Yamashita S; Matsukura G; Tazawa R; Shiga T; Ebato M; Satoh H; Ishii S
Genet Med; 2019 Jan; 21(1):44-52. PubMed ID: 29543226
[TBL] [Abstract][Full Text] [Related]
6. Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease.
Sueoka H; Ichihara J; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(5):e0127048. PubMed ID: 25965380
[TBL] [Abstract][Full Text] [Related]
7. Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients.
Shiga T; Tsukimura T; Kubota T; Togawa T; Sakuraba H
Intern Med; 2024 Jun; 63(11):1531-1537. PubMed ID: 37866916
[TBL] [Abstract][Full Text] [Related]
8. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
9. Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease.
Nowak A; Mechtler T; Kasper DC; Desnick RJ
Mol Genet Metab; 2017 Aug; 121(4):320-324. PubMed ID: 28663131
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation.
Auray-Blais C; Lavoie P; Boutin M; Ntwari A; Hsu TR; Huang CK; Niu DM
Clin Chim Acta; 2017 Mar; 466():185-193. PubMed ID: 28108302
[TBL] [Abstract][Full Text] [Related]
11. Globotriaosylsphingosine (Lyso-Gb
Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.
Stiles AR; Zhang H; Dai J; McCaw P; Beasley J; Rehder C; Koeberl DD; McDonald M; Bali DS; Young SP
Mol Genet Metab; 2020 Jul; 130(3):209-214. PubMed ID: 32418857
[TBL] [Abstract][Full Text] [Related]
13. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.
Sakuraba H; Togawa T; Tsukimura T; Kato H
Clin Exp Nephrol; 2018 Aug; 22(4):843-849. PubMed ID: 29288396
[TBL] [Abstract][Full Text] [Related]
14. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
Talbot A; Nicholls K; Fletcher JM; Fuller M
Mol Genet Metab; 2017 Sep; 122(1-2):121-125. PubMed ID: 28847675
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of lyso-globotriaosylsphingosine in dried blood spots in the differential diagnosis between multiple sclerosis and Anderson-Fabry's disease.
Olivera S; Iñiguez C; García-Fernández L; Sierra JL; Camón AM; Menao S; Torralba MÁ
Mult Scler Relat Disord; 2020 Feb; 38():101466. PubMed ID: 31715500
[TBL] [Abstract][Full Text] [Related]
16. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
[TBL] [Abstract][Full Text] [Related]
17. Accuracy diagnosis improvement of Fabry disease from dried blood spots: Enzyme activity, lyso-Gb3 accumulation and GLA gene sequencing.
Delarosa-Rodríguez R; Santotoribio JD; Paula HA; González-Meneses A; García-Morillo S; Jiménez-Arriscado P; Guerrero JM; Macher HC
Clin Genet; 2021 Jun; 99(6):761-771. PubMed ID: 33527381
[TBL] [Abstract][Full Text] [Related]
18. Globotriaosylsphingosine (lyso-Gb
Effraimidis G; Feldt-Rasmussen U; Rasmussen ÅK; Lavoie P; Abaoui M; Boutin M; Auray-Blais C
J Med Genet; 2021 Oct; 58(10):692-700. PubMed ID: 32963035
[TBL] [Abstract][Full Text] [Related]
19. Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy.
Yamashita S; Saotome M; Satoh H; Kajihara J; Mochizuki Y; Mizuno K; Nobuhara M; Miyajima K; Kumazawa A; Tominaga H; Takase H; Tawarahara K; Wakahara N; Matsunaga M; Wakabayashi Y; Matsumoto Y; Terada H; Sano M; Ohtani H; Urushida T; Hayashi H; Ishii S; Maruyama H; Maekawa Y
Circ J; 2019 Aug; 83(9):1901-1907. PubMed ID: 31308318
[TBL] [Abstract][Full Text] [Related]
20. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.
Ferreira S; Auray-Blais C; Boutin M; Lavoie P; Nunes JP; Martins E; Garman S; Oliveira JP
Clin Chim Acta; 2015 Jul; 447():96-104. PubMed ID: 26070511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
